摘要
目的探讨注射用纤溶酶、低分子肝素钙联用对肺栓塞易栓因素患者的临床治疗价值。方法选取我院2015年9月至2018年4月收治的肺栓塞易栓因素患者86例作为研究对象,随机分为两组各43例。对照组在常规治疗基础上加用低分子肝素钙,研究组在常规治疗基础上加用低分子肝素钙联合注射用纤溶酶,两组均连续用药7 d。结果两组患者用药前的相关实验室指标比较,差异均无统计学意义(P>0.05);用药后,研究组的Fbg、D-D、HCT下降幅度优于对照组(P<0.05);用药后,研究组的tPA、PAI-1水平较用药前显著下降(P<0.05),对照组用药前后上述指标无显著变化(P>0.05);用药后,研究组的PaO2水平上升幅度优于对照组(P<0.05)。两组用药期间的药物相关不良反应发生率无统计学差异(P>0.05)。结论低分子肝素钙联合注射用纤溶酶治疗肺栓塞易栓因素患者效果显著,有利于保障其生活质量、生命安全。
Objective To investigate the clinical treatment value of plasmin for injection combined with low molecular weight heparin calcium for patients with thrombosis-prone factors of pulmonary embolism.Methods 86 patients with thrombosis-prone factors of pulmonary embolism in our hospital from September 2015 to April 2018 were randomly divided into two groups,with 43 cases in each group.On the basis of conventional treatment,the control group was treated with low molecular weight heparin calcium,and the study group was treated with low molecular weight heparin calcium combined with plasmin for injection.Both groups were consecutively administered for 7 d.Results No significant difference was found between the two groups in the related laboratory indicators before treatment(P>0.05);After treatment,the study group had more significantly decreased Fbg,D-D and HCT than the control group(P<0.05);After treatment,the tPA and PAI-1 levels in the study group decreased significantly(P<0.05),while the tPA and PAI-1 levels in the control group had no significant change compared with those before treatment(P>0.05);After treatment,the study group had more significantly increased PaO2 level than the control group(P<0.05).No statistical difference was found between two groups in the incidences of drug-related adverse reactions during treatment(P>0.05).Conclusions Plasmin for injection combined with low molecular weight heparin calcium for the treatment of patients with thrombosis-prone factors of pulmonary embolism has signific ant effect,and is conducive to ensuring patients'quality of life and safety of life.
作者
祁雯
柯有力
QI Wen;KE Youli(General and Thoracic Vascular Surgery Department,Wuhan First Hospital,Wuhan 430022,China)
出处
《临床医学工程》
2019年第10期1355-1356,共2页
Clinical Medicine & Engineering
关键词
肺栓塞
易栓因素
注射用纤溶酶
低分子肝素钙
Pulmonary embolism
Thrombosis-prone factors
Plasmin for injection
Low molecular weight heparin calcium
